Rudin, Charles

Publications

Sort by

Co-Author Network

selected publications

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Academic Article GET IT
Correction: SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. 2024 GET IT
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Science advances. 2024 Academic Article GET IT
Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma. The Journal of clinical endocrinology and metabolism. 2024 Academic Article GET IT
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification. JCO precision oncology. 2024 Academic Article GET IT
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer. JCO precision oncology. 2024 Academic Article GET IT
TGF-β and RAS jointly unmask primed enhancers to drive metastasis. Cell. 2024 Academic Article GET IT
Chromothripsis-mediated small cell lung carcinoma. Cancer discovery. 2024 Academic Article GET IT
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in cancer. 2024 Review GET IT
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer. European journal of cancer. 2024 Academic Article GET IT
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. Journal of hematology & oncology. 2024 Academic Article GET IT
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. Signal transduction and targeted therapy. 2024 Academic Article GET IT
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Academic Article GET IT
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. Cancer cell. 2024 Academic Article GET IT
Times cited: 3
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ precision oncology. 2024 Academic Article GET IT
Imaging with [⁸⁹Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. The Lancet. Oncology. 2024 Academic Article GET IT
Times cited: 3
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Molecular cancer. 2024 Academic Article GET IT
Biomarkers associated with pulmonary exacerbations in a randomized trial of nintedanib for radiation pneumonitis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2024 Academic Article GET IT
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Academic Article GET IT
Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions. Science advances. 2024 Academic Article GET IT
Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases. JCO precision oncology. 2024 Academic Article GET IT
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer. Science advances. 2024 Academic Article GET IT
Times cited: 7
Role of CD38 in anti-tumor immunity of small cell lung cancer. Frontiers in immunology. 2024 Academic Article GET IT
A Lung Cancer Mouse Model Database. 2024 GET IT
Functional Characterisation of the ATOH1 Molecular Subtype Indicates a Pro-Metastatic Role in Small Cell Lung Cancer. 2024 GET IT
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer cell. 2024 Academic Article GET IT
First-in-human imaging with [⁸⁹Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate. 2024 GET IT
Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2024 Academic Article GET IT
Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation. Cancer immunology research. 2023 Academic Article GET IT
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet (London, England). 2023 Academic Article GET IT
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Cancer discovery. 2023 Academic Article GET IT
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell reports. 2023 Academic Article GET IT
Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden and recurrent somatic MLH1 inactivation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023 Academic Article GET IT
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. 2023 GET IT
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. Frontiers in oncology. 2023 Academic Article GET IT
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC. JTO clinical and research reports. 2023 Academic Article GET IT
Breathing room - focusing on the 'other' lung cancer. Nature cancer. 2023 Academic Article GET IT
De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. The oncologist. 2023 Academic Article GET IT
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. The oncologist. 2023 Academic Article GET IT
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Science translational medicine. 2023 Academic Article GET IT
Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growth. 2023 GET IT
Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study. Journal for immunotherapy of cancer. 2023 Academic Article GET IT
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer. 2023 GET IT
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. Journal of hematology & oncology. 2023 Review GET IT
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023 Academic Article GET IT
Times cited: 30
CRACD loss promotes small cell lung cancer tumorigenesis via EZH2-mediated immune evasion. 2023 GET IT
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023 Academic Article GET IT
Times cited: 5
Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies. Nature immunology. 2023 Academic Article GET IT
Times cited: 15
IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. The Journal of clinical investigation. 2023 Academic Article GET IT
Times cited: 47
Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Editorial Article GET IT
In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancer. 2023 GET IT
Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer cell. 2023 Academic Article GET IT
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer cell. 2023 Academic Article GET IT
Inference of single cell profiles from histology stains with the Single-Cell omics from Histology Analysis Framework (SCHAF). 2023 GET IT
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis. International journal of radiation oncology, biology, physics. 2023 Academic Article GET IT
Times cited: 1
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. ESMO open. 2023 Academic Article GET IT
Times cited: 6
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for immunotherapy of cancer. 2023 Academic Article GET IT
Times cited: 16
The ectonucleotidase CD39 identifies tumor-reactive CD8⁺ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2022 Academic Article GET IT
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Academic Article GET IT
Times cited: 42
Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library. Genome medicine. 2022 Academic Article GET IT
Times cited: 2
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nature medicine. 2022 Academic Article GET IT
Times cited: 64
Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Editorial Article GET IT
Times cited: 35
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. Nature reviews. Clinical oncology. 2022 Review GET IT
Times cited: 2
Protocol to dissociate, process, and analyze the human lung tissue using single-cell RNA-seq. STAR protocols. 2022 Academic Article GET IT
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Academic Article GET IT
Times cited: 12
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. Annals of oncology : official journal of the European Society for Medical Oncology. 2022 Academic Article GET IT
Times cited: 25
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 25
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study. JTO clinical and research reports. 2022 Academic Article GET IT
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1. Nature communications. 2022 Academic Article GET IT
Times cited: 14
cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nature cancer. 2022 Academic Article GET IT
Times cited: 53
PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry. Cancer discovery. 2022 Academic Article GET IT
Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 10
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2022 Academic Article GET IT
Times cited: 22
POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Academic Article GET IT
Times cited: 41
Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Academic Article GET IT
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. JCO precision oncology. 2022 Academic Article GET IT
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular cell. 2022 Academic Article GET IT
Times cited: 11
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell reports. 2022 Academic Article GET IT
Times cited: 58
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. Clinical lung cancer. 2022 Academic Article GET IT
Times cited: 3
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2022 Academic Article GET IT
Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nature communications. 2022 Academic Article GET IT
Times cited: 27
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 26
Inferring gene expression from cell-free DNA fragmentation profiles. Nature biotechnology. 2022 Academic Article GET IT
Times cited: 3
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022 Academic Article GET IT
Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2022 Academic Article GET IT
Times cited: 21
Immune biomarkers and response to checkpoint inhibition of BRAF^V600 and BRAF non-V600 altered lung cancers. British journal of cancer. 2021 Academic Article GET IT
Times cited: 15
Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer discovery. 2021 Academic Article GET IT
Times cited: 79
Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. Cancer discovery. 2021 Academic Article GET IT
Times cited: 25
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy. Cancer research. 2021 Academic Article GET IT
Times cited: 21
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. JTO clinical and research reports. 2021 Academic Article GET IT
Times cited: 8
A CRISPR Activation Screen Identifies an Atypical Rho GTPase That Enhances Zika Viral Entry. Viruses. 2021 Academic Article GET IT
Times cited: 9
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. Journal of hematology & oncology. 2021 Academic Article GET IT
Times cited: 36
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer cell. 2021 Academic Article GET IT
Times cited: 185
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. iScience. 2021 Academic Article GET IT
Times cited: 14
Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. Cancer discovery. 2021 Academic Article GET IT
Times cited: 55
Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle. Cell reports. Medicine. 2021 Comment GET IT
Times cited: 2
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer cell. 2021 Academic Article GET IT
Times cited: 69
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 18
Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma. Cancer research. 2021 Academic Article GET IT
Times cited: 10
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature communications. 2021 Academic Article GET IT
Times cited: 87
Tim-4⁺ cavity-resident macrophages impair anti-tumor CD8⁺ T cell immunity. Cancer cell. 2021 Academic Article GET IT
Times cited: 109
Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. Genes & development. 2021 Academic Article GET IT
Times cited: 6
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nature cancer. 2021 Academic Article GET IT
Times cited: 80
N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection. Viruses. 2021 Academic Article GET IT
Times cited: 6
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^☆. Annals of oncology : official journal of the European Society for Medical Oncology. 2021 Guideline GET IT
Times cited: 267
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. Bioconjugate chemistry. 2021 Academic Article GET IT
Times cited: 10
Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harbor perspectives in medicine. 2021 Review GET IT
Times cited: 32
Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors. Endocrine-related cancer. 2021 Academic Article GET IT
Times cited: 4
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 50
KRAS ^G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 23
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 70
Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis. 2021 GET IT
Small-cell lung cancer. Nature reviews. Disease primers. 2021 Review GET IT
Times cited: 684
A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. Cancer discovery. 2020 Academic Article GET IT
Times cited: 9
TMEM41B Is a Pan-flavivirus Host Factor. Cell. 2020 Academic Article GET IT
Times cited: 113
Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell reports. 2020 Academic Article GET IT
Times cited: 139
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 38
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. Journal of medicinal chemistry. 2020 Academic Article GET IT
Times cited: 54
TMEM41B is a pan-flavivirus host factor. 2020 GET IT
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 Academic Article GET IT
Times cited: 286
Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 Academic Article GET IT
Times cited: 1
Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy. Molecular cancer therapeutics. 2020 Academic Article GET IT
Times cited: 8
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell. 2020 Academic Article GET IT
Times cited: 740
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Frontiers in oncology. 2020 Review GET IT
Times cited: 272
Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 19
CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 20
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 146
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer cell. 2020 Academic Article GET IT
Times cited: 190
Role of mTOR As an Essential Kinase in SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 Academic Article GET IT
Times cited: 13
COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 196
Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance. 2020 GET IT
Times cited: 1
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 468
Targeted Therapies and Biomarkers in Small Cell Lung Cancer. Frontiers in oncology. 2020 Review GET IT
Times cited: 66
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. Lung cancer (Amsterdam, Netherlands). 2020 Academic Article GET IT
Times cited: 19
Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature communications. 2020 Academic Article GET IT
Times cited: 29
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2020 Academic Article GET IT
Times cited: 44
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 172
Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. Nature cancer. 2020 Academic Article GET IT
Times cited: 25
Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature reviews. Clinical oncology. 2020 Review GET IT
Times cited: 281
Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020 Academic Article GET IT
Times cited: 231
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 85
Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nature medicine. 2020 Academic Article GET IT
Times cited: 234
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 213
New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 Review GET IT
Times cited: 120
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 8
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2019 Academic Article GET IT
Times cited: 19
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature medicine. 2019 Academic Article GET IT
Times cited: 477
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 193
Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nature cell biology. 2019 Academic Article GET IT
Times cited: 274
Epigenetic targeting of DNA repair in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019 Article GET IT
Times cited: 3
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. The oncologist. 2019 Review GET IT
Times cited: 40
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European journal of cancer. 2019 Academic Article GET IT
Times cited: 25
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 63
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 215
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. Cancer. 2019 Academic Article GET IT
Times cited: 55
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta oncologica (Stockholm, Sweden). 2019 Academic Article GET IT
Times cited: 8
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 36
Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Editorial Article GET IT
Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. 2019 GET IT
Times cited: 16
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 247
Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 16
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 98
Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 66
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 113
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 50
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature reviews. Cancer. 2019 Review GET IT
Times cited: 719
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 313
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. Investigational new drugs. 2019 Academic Article GET IT
Times cited: 39
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 119
Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 30
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2019 Academic Article GET IT
Times cited: 62
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. 2019 GET IT
Times cited: 63
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Science signaling. 2019 Academic Article GET IT
Times cited: 144
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European journal of cancer. 2019 Academic Article GET IT
Times cited: 71
ONECUT2 is a driver of neuroendocrine prostate cancer. Nature communications. 2019 Academic Article GET IT
Times cited: 162
Peptide-based PET quantifies target engagement of PD-L1 therapeutics. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 102
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science (New York, N.Y.). 2018 Academic Article GET IT
Times cited: 266
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 92
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 242
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 85
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 2018 Academic Article GET IT
Times cited: 134
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 254
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 270
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 67
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 298
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer discovery. 2018 Academic Article GET IT
Times cited: 1094
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 778
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer discovery. 2018 Academic Article GET IT
Times cited: 151
Looking ahead to new therapies in small cell lung cancer. Clinical advances in hematology & oncology : H&O. 2018 Article GET IT
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 1060
Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nature communications. 2018 Academic Article GET IT
Times cited: 71
Small-cell lung cancer in the era of immunotherapy. Translational lung cancer research. 2017 Editorial Article GET IT
Times cited: 5
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 87
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 320
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature medicine. 2017 Academic Article GET IT
Times cited: 459
Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2017 Academic Article GET IT
Times cited: 54
A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Molecular cancer research : MCR. 2017 Academic Article GET IT
Times cited: 70
Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Advances in radiation oncology. 2017 Academic Article GET IT
Times cited: 36
Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2017 Academic Article GET IT
Times cited: 38
Atezolizumab for the treatment of non-small cell lung cancer. Expert review of clinical pharmacology. 2017 Review GET IT
Times cited: 34
Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. The Journal of clinical investigation. 2017 Academic Article GET IT
Times cited: 55
Scientific Advances in Thoracic Oncology 2016. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Review GET IT
Times cited: 40
Unravelling the biology of SCLC: implications for therapy. Nature reviews. Clinical oncology. 2017 Information Resource GET IT
Times cited: 336
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer research. 2017 Academic Article GET IT
Times cited: 85
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Molecular cancer therapeutics. 2017 Academic Article GET IT
Times cited: 34
Histone Code Aberrancies in Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Editorial Article GET IT
Times cited: 2
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 490
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of oncology. 2017 Review GET IT
Times cited: 21
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 500
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer cell. 2017 Academic Article GET IT
Times cited: 367
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 39
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC. EJNMMI research. 2017 Academic Article GET IT
Times cited: 15
Small-cell lung cancer in 2016: Shining light on novel targets and therapies. Nature reviews. Clinical oncology. 2016 Article GET IT
Times cited: 28
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 440
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 372
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 858
Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis. PloS one. 2016 Academic Article GET IT
Times cited: 47
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical lung cancer. 2016 Academic Article GET IT
Times cited: 31
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 258
Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation. Radiology. 2016 Academic Article GET IT
Times cited: 20
P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science translational medicine. 2016 Academic Article GET IT
Times cited: 155
A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Academic Article GET IT
Times cited: 311
Missing the mark in FGFR1-amplified squamous cell cancer of the lung. Cancer. 2016 Editorial Article GET IT
Times cited: 5
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 339
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Academic Article GET IT
Times cited: 65
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 55
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 356
Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails". JAMA oncology. 2016 Article GET IT
Times cited: 30
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 50
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Information Resource GET IT
Times cited: 142
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical lung cancer. 2016 Academic Article GET IT
Times cited: 118
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell reports. 2015 Academic Article GET IT
Times cited: 53
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 7884
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 165
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Science translational medicine. 2015 Academic Article GET IT
Times cited: 457
Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 187
Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy. PloS one. 2015 Academic Article GET IT
Times cited: 6
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. Journal of the American Academy of Dermatology. 2015 Academic Article GET IT
Times cited: 136
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer discovery. 2015 Academic Article GET IT
Times cited: 490
Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters. PloS one. 2015 Academic Article GET IT
Times cited: 21
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature communications. 2015 Academic Article GET IT
Times cited: 495
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. 2015 Academic Article GET IT
Times cited: 183
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer cell. 2015 Academic Article GET IT
Times cited: 308
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature genetics. 2015 Academic Article GET IT
Times cited: 413
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral oncology. 2015 Academic Article GET IT
Times cited: 74
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2015 Academic Article GET IT
Times cited: 27
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 119
Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 78
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 106
Small cell lung cancer: where do we go from here?. Cancer. 2014 Information Resource GET IT
Times cited: 475
Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatric blood & cancer. 2014 Academic Article GET IT
Times cited: 63
Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-oncology. 2014 Academic Article GET IT
Times cited: 76
A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 34
RET mutations in neuroendocrine tumors: including small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Editorial Article GET IT
Times cited: 10
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer medicine. 2014 Academic Article GET IT
Times cited: 25
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 28
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 Academic Article GET IT
Times cited: 1404
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung cancer (Amsterdam, Netherlands). 2014 Academic Article GET IT
Times cited: 28
Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer research. 2014 Academic Article GET IT
Times cited: 50
MYC, MAX, and small cell lung cancer. Cancer discovery. 2014 Comment GET IT
Times cited: 11
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 36
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 91
Survival after community diagnosis of early-stage non-small cell lung cancer. The American journal of medicine. 2014 Academic Article GET IT
Times cited: 48
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013 Academic Article GET IT
Times cited: 340
Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2013 Academic Article GET IT
Times cited: 83
The twist box domain is required for Twist1-induced prostate cancer metastasis. Molecular cancer research : MCR. 2013 Academic Article GET IT
Times cited: 63
Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. Journal of the National Cancer Institute. 2013 Academic Article GET IT
Times cited: 108
Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 133
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 152
The future of epigenetic therapy in solid tumours--lessons from the past. Nature reviews. Clinical oncology. 2013 Information Resource GET IT
Times cited: 291
Characteristics of lung cancers harboring NRAS mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 126
ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Molecular cancer therapeutics. 2013 Academic Article GET IT
Times cited: 31
Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Molecular cancer. 2013 Academic Article GET IT
Times cited: 43
Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. Molecular cancer research : MCR. 2013 Academic Article GET IT
Times cited: 56
Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo. Molecular cancer therapeutics. 2013 Academic Article GET IT
Times cited: 42
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer cell. 2013 Academic Article GET IT
Times cited: 299
Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2013 Information Resource GET IT
Times cited: 10
Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. International journal of radiation oncology, biology, physics. 2012 Academic Article GET IT
Times cited: 40
Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001. The Journal of general virology. 2012 Academic Article GET IT
Times cited: 15
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature genetics. 2012 Academic Article GET IT
Times cited: 868
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 1190
Crizotinib in the treatment of non-small-cell lung cancer. Expert opinion on pharmacotherapy. 2012 Information Resource GET IT
Times cited: 53
Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS genetics. 2012 Academic Article GET IT
Times cited: 90
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 462
Novel therapeutic approaches for small cell lung cancer: the future has arrived. Current problems in cancer. 2012 Academic Article GET IT
Times cited: 6
Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. International journal of cancer. 2011 Academic Article GET IT
Times cited: 409
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer discovery. 2011 Academic Article GET IT
Times cited: 584
A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Molecular cancer therapeutics. 2011 Academic Article GET IT
Times cited: 78
Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Molecular cancer research : MCR. 2011 Academic Article GET IT
Times cited: 37
Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling. Journal of medicinal chemistry. 2011 Academic Article GET IT
Times cited: 46
A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 142
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer biology & therapy. 2011 Academic Article GET IT
Times cited: 25
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer research. 2011 Academic Article GET IT
Times cited: 144
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2011 Academic Article GET IT
Times cited: 86
Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 119
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 107
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 481
Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 42
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 2011 Academic Article GET IT
Times cited: 517
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 494
The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 36
Geographic proximity and racial disparities in cancer clinical trial participation. Journal of the National Comprehensive Cancer Network : JNCCN. 2010 Academic Article GET IT
Skin deep and deeper: multiple pathways in basal cell carcinogenesis. Cancer prevention research (Philadelphia, Pa.). 2010 Comment GET IT
Times cited: 4
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer chemotherapy and pharmacology. 2010 Academic Article GET IT
Times cited: 67
Beyond the scalpel: targeting hedgehog in skin cancer prevention. Cancer prevention research (Philadelphia, Pa.). 2010 Comment GET IT
Times cited: 8
Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Molecular cancer research : MCR. 2009 Academic Article GET IT
Times cited: 66
Cancer stem cells. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Conference Paper GET IT
Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Information Resource GET IT
Times cited: 443
Lung cancer in never smokers: molecular profiles and therapeutic implications. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Information Resource GET IT
Times cited: 133
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. The New England journal of medicine. 2009 Academic Article GET IT
Times cited: 891
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (New York, N.Y.). 2009 Academic Article GET IT
Times cited: 753
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer research. 2009 Academic Article GET IT
Times cited: 386
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. The oncologist. 2009 Academic Article GET IT
Times cited: 21
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 42
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2008 Academic Article GET IT
Times cited: 172
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer research. 2008 Academic Article GET IT
Times cited: 190
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 203
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 165
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008 Academic Article GET IT
Times cited: 7
Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. Journal of the National Cancer Institute. 2007 Academic Article GET IT
Times cited: 189
An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 22
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007 Academic Article GET IT
Times cited: 11
DNA cleavage and Trp53 differentially affect SINE transcription. Genes, chromosomes & cancer. 2007 Academic Article GET IT
Times cited: 10
Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends in molecular medicine. 2007 Information Resource GET IT
Times cited: 26
SVF1 regulates cell survival by affecting sphingolipid metabolism in Saccharomyces cerevisiae. Genetics. 2006 Academic Article GET IT
Times cited: 16
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung cancer (Amsterdam, Netherlands). 2006 Academic Article GET IT
Times cited: 34
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006 Academic Article GET IT
Times cited: 21
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2006 Academic Article GET IT
Times cited: 27
Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 75
Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate. Molecular cancer research : MCR. 2005 Academic Article GET IT
Times cited: 13
Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in Saccharomyces cerevisiae. Yeast (Chichester, England). 2005 Academic Article GET IT
Times cited: 21
Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. The Journal of thoracic and cardiovascular surgery. 2005 Academic Article GET IT
Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Molecular cancer therapeutics. 2004 Academic Article GET IT
Times cited: 90
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 72
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 27
Akt stimulates aerobic glycolysis in cancer cells. Cancer research. 2004 Academic Article GET IT
Times cited: 1046
Reassessing autotransplantation for acute myeloid leukaemia in first remission - a matched pair analysis of autologous marrow vs peripheral blood stem cells. Bone marrow transplantation. 2004 Academic Article GET IT
Times cited: 9
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 151
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 842
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 140
Human Alu element retrotransposition induced by genotoxic stress. Nature genetics. 2003 Academic Article GET IT
Times cited: 93
Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. Virology. 2003 Academic Article GET IT
Times cited: 95
Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo. Oncogene. 2003 Academic Article GET IT
Times cited: 30
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2003 Academic Article GET IT
Times cited: 35
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer research. 2003 Academic Article GET IT
Times cited: 153
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung cancer (Amsterdam, Netherlands). 2002 Academic Article GET IT
Times cited: 19
Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolism. The Journal of biological chemistry. 2002 Academic Article GET IT
Times cited: 52
Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer research. 2002 Academic Article GET IT
Times cited: 64
Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer. Clinical lung cancer. 2002 Academic Article GET IT
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Academic Article GET IT
Times cited: 141
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 70
Mobile genetic element activation and genotoxic cancer therapy: potential clinical implications. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2002 Information Resource GET IT
Times cited: 40
ONYX-015. Onyx Pharmaceuticals. Current opinion in investigational drugs (London, England : 2000). 2001 Information Resource GET IT
Times cited: 31
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 128
A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Investigational new drugs. 2001 Academic Article GET IT
Times cited: 16
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Investigational new drugs. 2001 Academic Article GET IT
Times cited: 20
Transcriptional activation of short interspersed elements by DNA-damaging agents. Genes, chromosomes & cancer. 2001 Academic Article GET IT
Times cited: 95
A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clinical lung cancer. 2000 Academic Article GET IT
Cell line dependence of Bcl-2-induced alteration of glutathione handling. Oncogene. 2000 Academic Article GET IT
Times cited: 34
Early release of mitochondrial cytochrome c and expression of mitochondrial epitope 7A6 with a porphyrin-derived photosensitizer: Bcl-2 and Bcl-xL overexpression do not prevent early mitochondrial events but still depress caspase activity. Laboratory investigation; a journal of technical methods and pathology. 1999 Academic Article GET IT
Times cited: 71
Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer. 1999 Academic Article GET IT
Times cited: 102
B-cell development and maturation. Seminars in oncology. 1998 Information Resource GET IT
Times cited: 28
Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer research. 1998 Article GET IT
Times cited: 153
A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas. Cancer research. 1998 Academic Article GET IT
Times cited: 61
Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annual review of medicine. 1997 Information Resource GET IT
Times cited: 308
Apoptotic signaling in lymphocytes. Current opinion in hematology. 1996 Information Resource GET IT
Times cited: 9
Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 1995 Academic Article GET IT
Times cited: 369
Two conserved essential motifs of the murine immunoglobulin lambda enhancers bind B-cell-specific factors. Molecular and cellular biology. 1992 Academic Article GET IT
Times cited: 24
Identification and localization of an enhancer for the human lambda L chain Ig gene complex. Journal of immunology (Baltimore, Md. : 1950). 1991 Academic Article GET IT
Times cited: 25
Precursors of both conventional and Ly-1 B cells can escape feedback inhibition of Ig gene rearrangement. Journal of immunology (Baltimore, Md. : 1950). 1991 Academic Article GET IT
Times cited: 5
Differential splicing of thymosin beta 4 mRNA. Journal of immunology (Baltimore, Md. : 1950). 1990 Academic Article GET IT
Times cited: 23
A novel enhancer in the immunoglobulin lambda locus is duplicated and functionally independent of NF kappa B. Genes & development. 1990 Academic Article GET IT
Times cited: 80
Inhibition of immunoglobulin gene rearrangement by the expression of a lambda 2 transgene. The Journal of experimental medicine. 1989 Academic Article GET IT
Times cited: 47

more ...

less ...

Background

education and training

Ph.D., University of Chicago Pritzker School of Medicine 91
M.D., University of Chicago Pritzker School of Medicine 1993
B.S., University of Wisconsin, Milwaukee 1986

Contact

full name

Charles Rudin

VIVO Weill Cornell Medical College

Charles Rudin Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email